Facebook
Twitter
LinkedIn
ForwardCANGRELOR-UPSTREAM P2Y12 INHIBITOR USE--EPISODE #2 FROM THE CAMEO REGISTRY
- The Duke Clinical Research Institute Principal Investigator of the CAMEO registry, Dr. Jennifer Rymer, and Dominick Angiolillo, Professor and Chief of the Division of Cardiology, the Medical Director of the University of Florida Health Cardiovascular Center in Jacksonville, the Medical Director of the Cardiovascular Research Program, and the Program Director of the Interventional Cardiology Fellowship host a podcast in which They discuss some of their recent research examining cangrelor use in the setting of upstream P2Y12 inhibitor use. Tune in to hear Angiolillo and Rymer break down the results of their studies in which they attempted to rule out drug-drug interactions or bleeding risk among cangrelor-treated patients who have been pretreated with ticagrelor.
Target Audience
- Fellows
- Medical Students
- Nurses
- Nurse Practitioners
- Physicians
- Physician Assistants
- Pharmacy Technicians
- Pharmacists
- Residents
Learning Objectives
1. To discuss research from the CAMEO Registry and learn how clinicians are using cangrelor to help patients with acute myocardial infarction who have been pretreated with a P2Y12 inhibitor.
2. To learn about findings from the Switching Antiplatelet Therapy-5 (SWAP-5) study.
3. To discuss and understand the safety of treating patients with cangrelor doses after they have received upstream P2Y12 inhibitors.
Durham, NC
27705
United States
- Jennifer Rymer
Speaker
- ACPE - Pharmacy Technician
- ACPE - Pharmacist
- AMA PRA Category 1 Credit(s)
- ANCC
- Attendance
Available Credit
- 0.25 ACPE - Pharmacist
- 0.25 ACPE - Pharmacy Technician
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 ANCC
- 0.25 Attendance
- 0.03 IACET CEU
- 0.25 JA Credit - AH
- 0.25 Approved for AMA PRA Category 1 Credit(s)™